Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Fewer mothers in Washington, D.C., refused to have their newborns receive an initial birth dose of the hepatitis B vaccine (Engerix-B, Recombivax HB) in recent

Apogee Ther­a­peu­tics and Sagimet Bio­sciences of­fered new de­tails on their IPO plans Mon­day morn­ing, say­ing they look to raise $228 mil­lion and $66 mil­lion in